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Asymptotic and Finite Sample Behavior
of Net Reclassification Indices
Zheyu Wang
Abstract
The Net Reclassification Index (NRI) introduced by Pencina and colleagues [1,
2] is designed to quantify the prediction increment provided by a new biomarker. It
has become popular for evaluating and selecting novel markers. The published variance
formulae for NRI statistics do not account for the fact that risks are estimated based on
risk models fit to data, and thus are not valid in practice when estimated risks are used
[3]. Kerr and colleagues [4] showed that the confidence intervals constructed based on a
bootstrap estimate of the variance and Normal approximation had the best performance
among various methods they examined, including the one based on bootstrap quantiles.
This paper establishes asymptotic Normality of NRI statistics when true risks are
unknown and are estimated. Our results provide theoretical support for constructing
confidence intervals for NRI statistics based on a Normal approximation. We also derive
explicit variance formulae for NRI statistics that are calculated based on estimated
risks. In addition, we examine finite sample distributional behavior of NRI statistics in
a simulation study. These results provide some guidance on the sample size required
for adopting a Normal approximation for NRI inference in practice.
Keyworks: Net reclassification index; incremental value; asymptotic Normality;
sampling distribution; biomarker; risk models
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1 Introduction
Risk prediction is key in medical decision making as well as in health policy development.
Accurate risk prediction can assist clinicians in recommending the most beneficial treatment
to patients while avoiding unnecessary, invasive, or costly procedures. It is also crucial for
health policy makers to develop well-informed strategies for the whole population. This
has led to continuous efforts to improve prediction models and successive discovery of novel
markers. For example, breast density [5, 6] and genetic polymorphisms [7, 8, 9] are proposed
for predicting breast cancer risk in addition to traditional factors in the Gail model [10, 11].
Numerous studies have been conducted in recent years to evaluate candidate markers for
cardiovascular event upon factors in the standard Framingham risk score [12]. An important
question is how best to assess and quantify the improvement gained from incorporating new
biomarkers into risk prediction models.
Various metrics have been proposed to quantify the prediction increment, or incremental
value, of a biomarker [13]. Change in the area under the receiver operating characteristic
curve (∆AUC) is the most popular single number summary index. However, AUC has been
criticized because it does not measure a clinically meaningful quantity, and because it is a
broad summary of changes in risk models that incorporates irrelevant information [14, 15, 16].
To overcome these limitations, Pencina and colleagues [1] proposed the Net Reclassification
Index (NRI) as a new measure of incremental value. The original definition of NRI is based
on a reclassification table with predefined risk categories. It is conceived from the idea that
a useful biomarker will lead to more diseased subjects in higher risk categories and more
healthy subjects in lower risk categories. Consequently, it contains two parts, the “event”
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NRI, and the “nonevent” NRI, as follows,
NRI(event) = P (up|event)− P (down|event),
NRI(nonevent) = P (down|nonevent)− P (up|nonevent),
NRI = NRI(event) +NRI(nonevent).
Here, “event” denotes subjects with disease or other medical conditions of interest (“cases”)
and “nonevent” denotes controls. “Up” indicates that the risk predication based on the model
with the new biomarker moves an individual into a higher risk category compared to the
old model with baseline predictors. “Down” indicates the reverse, that the risk predication
based on the new model moves an individual into a lower risk category compared to the old
model. Later, a “category-free” or “continuous” NRI was introduced [2] to avoid the need
for subjective and perhaps arbitrary risk thresholds, although this version of NRI shares
many of the same limitations as ∆AUC [4, 17]. Despite their limitations, NRI statistics have
become increasing popular, especially in cardiovascular research [18, 19].
A close examination of the asymptotic behavior of NRI statistics is necessary to correctly
gauge the uncertainty in the estimation and construct valid confidence intervals for inference.
Pencina and colleagues provided formulae [2] for NRI statistics comparing risks calculated
from the baseline risk model and risks calculated from the expanded risk model that includes
the new biomarker. Pepe et al. [3] pointed out that the variance formulae derived based on
fixed risk models, such as the ones in Pencina et al. [2], do not consider the variability in
regression model coefficient estimates, and thus are not valid when estimated risks are used.
Kerr et al. [4] illustrated this issue for NRI statistics with a simulation study. In practice,
the risk model is rarely known and is almost always estimated from the data. Therefore, it
is of interest to derive variance formulae for NRI statistics that account for the variability in
risk estimates and can be used in practical situations. Similarly, it is critical to examine the
asymptotic and finite sample distributional behavior of NRI statistics, since the commonly
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used method to construct a 95% confidence interval for a parameter θ, θˆ±1.96·ŜE(θˆ), requires
the distribution of θˆ to be approximately Normal, regardless of whether the standard error
estimate ŜE(θˆ) is obtained from a formula or by bootstrapping. The latter choice, confidence
interval for NRI statistics constructed based on a bootstrapped standard error and Normal
approximation, exhibited better coverage performance in the simulation study in Kerr et al.
[4] than various other confidence intervals they examined.
In this paper, we derive the asymptotic distribution of NRI statistics when the estimated
risks are used. We also study their finite sample behavior with simulations. Based on
the recommendation in Kerr et al. [4], we focuse on the category-free NRI and the two-
category NRI. This paper is organized as follows. Section 2 describes notation, settings and
assumptions. Section 3 and section 4 provide the derivations of the asymptotic distributions
of the category-free NRI and the two-category NRI, respectively. Section 5 studies the finite
sample behavior of NRI statistics via simulations. Section 6 concludes the paper with a
discussion.
2 Notation and settings
Suppose that we have a set of baseline risk factors X and a new biomarker Y . The task is
to evaluate the prediction increment introduced by this new biomaker. To do this, we want
to compare the classification performance of a new model with both X and Y as predictors
with that of the old model with only baseline predictors X.
Let F0 = FX be the distribution function of X, and F1 = FX,Y be the joint distribution
of X and Y . Let D be a binary variable indicate subject’s disease status, i.e., D equals
1 for cases and D equals 0 for controls. Suppose R0(β,X) = P (D = 1|X), R1(θ,X, Y ) =
P (D = 1|X, Y ) are the old and new risk models, respectively. We further suppose that the
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assumed risk models are the true risk models, i.e., there is no model misspecification. And
Fˆ0, Fˆ1, Rˆ0 = R0(βˆ,X) and Rˆ1 = R1(θˆ,X, Y ) are the corresponding estimated quantities. In
addition, n denotes the total sample size, and nD denotes the number of cases.
Assumptions:
(1)
√
n(βˆ − β)→d N(0,Σ0(β)) and
√
n(θˆ − θ)→d N(0,Σ1(θ)).
(2) Risk functions R0(r,X) and R1(s,X, Y ) are differentiable at true value r = β and s = θ.
(3) R−10 (r, t) and R
−1
1 (s, t) exist and are differentiable at r = β and s = θ.
(4) The set Ω = {(X, Y )|R0(r,X) 6= R1(s,X, Y )} has positive measure.
(5) F0 and F1 are continuous with positive density f0 and f1 on [0, 1] except on finite points.
(6) nD/n→p ρ > 0, as n→ +∞.
3 Asymptotic Distribution of a Category-Free NRI
A category-free NRI, also called continuous NRI, is the summation of an event NRI and a
nonevent NRI that are calculated based on continuous risks without pre-selected threshold.
Event NRI is defined as the probability that the new risk model provides a higher risk
than the old model among cases, P
(
R1(X, Y ) > R0(X)|D = 1
)
, minus the probability that
the new risk model provides a lower risk than the old model among cases, P
(
R1(X, Y ) <
R0(X)|D = 1
)
. Nonevent NRI is defined as the probability that the new risk model provides
a lower risk than the old model among controls, P
(
R1(X, Y ) < R0(X)|D = 0
)
, minus the
probability that the new risk model provides a higher risk than the old model among controls,
P
(
R1(X, Y ) > R0(X)|D = 0
)
.
In most situations, risks need to be estimated in addition to the four probabilities comparing
5
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them. So the estimated category-free NRI is calculated as follows,
N̂RI>0e = Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− Pˆ(Rˆ1(X, Y ) < Rˆ0(X)|D = 1),
N̂RI>0ne = Pˆ
(
Rˆ1(X, Y ) < Rˆ0(X)|D = 0
)− Pˆ(Rˆ1(X, Y ) > Rˆ0(X)|D = 0),
N̂RI>0 = N̂RI>0e + N̂RI
>0
ne .
NRI>0e characterizes the reclassification improvement among disease population, andNRI
>0
ne
summarizes the improvement among non-diseased population. Most often the costs and
benefits of these improvements will differ greatly for cases and controls. Therefore, it is
recommended to report these two components of the NRI statistic separately [4]. We will
derive the asymptotic results separately for N̂RI>0e and N̂RI
>0
ne .
3.1
We first consider N̂RI>0e .
N̂RI>0e = Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− P(Rˆ1(X, Y ) < Rˆ0(X)|D = 1)
= Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− (1− Pˆ(Rˆ1(X, Y ) > Rˆ0(X)|D = 1))
(By assumption 2)
= 2Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− 1.
√
n
[
Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− P(R1(X, Y ) > R0(X)|D = 1)]
=
{√
n
[
Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− P(Rˆ1(X, Y ) > Rˆ0(X)|D = 1)]}
+
{√
n
[
P
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− P(R1(X, Y ) > R0(X)|D = 1)]}
=
{
A
}
+
{
B
}
.
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Given
{
B
}
, or equivalently P
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)
, the first term
{
A
}
is the empirical
value of B derived from a proportion among the nD events. Therefore, conditioning on B,
A has mean 0 and binomial variance
var(A|B) = nP(Rˆ1(X, Y ) > Rˆ0(X)|D = 1)[1− P(Rˆ1(X, Y ) > Rˆ0(X)|D = 1)]/nD
.
=
1 +NRI>0e
2ρ
× 1−NRI
>0
e
2
=
1− (NRI>0e )2
4ρ
.
This can also be seen by noting that,
√
n
[
Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− Pˆ(R1(X, Y ) > R0(X)|D = 1)]
− √n[P(Rˆ1(X, Y ) > Rˆ0(X)|D = 1)− P(R1(X, Y ) > R0(X)|D = 1)] = op(1).
(By equicontinuity of process
√
nD(Pˆ − P ) and assumption 1, 2.)
Thus, A =
√
n
[
Pˆ
(
R1(X, Y ) > R0(X)|D = 1
)− P(R1(X, Y ) > R0(X)|D = 1)]+ op(1).
Because E(A|B) = 0, we have that var(A) = E[var(A|B)] .= [1− (NRI>0e )2]/4ρ. Moreover,
E(A|B) = 0 also implies A and B are uncorrelated. Hence,
var
(√
nN̂RI>0e
)
= 4var
{√
n
[
Pˆ
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− P(R1(X, Y ) > R0(X)|D = 1)]}
= 4
{
var(A) + var(B)
}
.
3.2
Now we turn to the variance of B =
√
n
[
P
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
) − P(R1(X, Y ) >
R0(X)|D = 1
)]
. The idea is to write it as a function of β and θ based on the asymptotic
distribution of Rˆ1(X, Y )− Rˆ0(X), and then apply the delta method.
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First, we derive asymptotic distribution of Rˆ1(X, Y ) − Rˆ0(X) by Taylor expansion and
assumption 1.
√
n
{[
Rˆ1(X, Y )− Rˆ0(X)
]− [R1(X, Y )−R0(X)]}
=
(∂R1(s,X, Y )
∂s
|s=θ
)T√
n(θˆ − θ)− (∂R0(r,X)
∂r
|r=β
)T√
n(βˆ − β) + op(1).
Thus,
√
n
{[
Rˆ1(X, Y )− Rˆ0(X)
]− [R1(X, Y )−R0(X)]}→d N(0,ΣR) by Slutskys theorem,
where
ΣR =
(∂R0(r,X)
∂r
|r=β
)T
Σ0(β)
(∂R0(r,X)
∂r
|r=β
)
+
(∂R1(s,X, Y )
∂s
|s=θ
)T
Σ1(θ)
(∂R1(s,X, Y )
∂s
|s=θ
)
−2(∂R0(r,X)
∂r
|r=β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂R1(s,X, Y )
∂s
|s=θ
)
.
In the above, the random variable
√
n
{[
Rˆ1(X, Y )− Rˆ0(X)
]− [R1(X, Y )− R0(X)]} is not
degenerate due to assumption 4. Nevertheless, when assumption 4 does not hold, that is,
R0(r,X) = R1(s,X, Y ), a.s., we have,
var(A)
.
=
1− (NRI>0e )2
4ρ
=
1
4ρ
6= 0.
Thus, var
(√
nN̂RI>0e
)
= 4
{
var(A) + var(B)
}
is dominated by var(A). In fact,
var
(√
nN̂RI>0e
)
= 4var(A) =
1
ρ
6= 0.
So the derivation can still go through. Thus, assumption 4 is not essential in establishing
asymptotic Normality of N̂RI>0e , and similarly of N̂RI
>0
ne . However, it is required in the
derivations for the two-category NRI as we will see in section 4.
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Let ψ0i and ψ1i be the influence functions of βˆ and θˆ, respectively, such that,
√
n(βˆ − β) = 1√
n
n∑
i=1
ψ0i(X) + op(1),
√
n(θˆ − θ) = 1√
n
n∑
i=1
ψ1i(X, Y ) + op(1).
Then,
ΣR =
(∂R0(β,X)
∂β
)T
var(ψ0i(X))
(∂R0(β,X)
∂β
)
+
(∂R1(θ,X, Y )
∂θ
)T
var(ψ1i(X, Y ))
(∂R1(θ,X, Y )
∂θ
)
−2(∂R0(β,X)
∂β
)T
cov
(
ψ0i(X), ψ1i(X, Y )
)(∂R1(θ,X, Y )
∂θ
)
.
Therefore, we have the following result asymptotically:
P
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)
= P
(
Rˆ1(X, Y )− Rˆ0(X) > 0|D = 1
)
.
=
∫
1− Φ(0−
[
R1(θ,X, Y )−R0(β,X)
]
Σ
1/2
R (β, θ)
)dF1D(X, Y )
=
∫
Φ(
[
R1(θ,X, Y )−R0(β,X)
]
Σ
1/2
R (β, θ)
)dF1D(X, Y ) ≡ H(β, θ),
where Φ(.) is the cdf of a standard Normal variable.
By Taylor expansion we have,
B =
√
n
[
P
(
Rˆ1(X, Y ) > Rˆ0(X)|D = 1
)− P(R1(X, Y ) > R0(X)|D = 1)]
=
(∂H(r, s)
∂r
|r=β,s=θ
)T√
n(βˆ − β) + (∂H(r, s)
∂s
|s=β,t=θ
)T√
n(θˆ − θ) + op(1).
Thus, B is asymptotically Normal with mean 0 and variance
var(B) =
(∂H(β, θ)
∂β
)T
Σ0(β)
(∂H(β, θ)
∂β
)
+
(∂H(β, θ)
∂θ
)T
Σ1(θ)
(∂H(β, θ)
∂θ
)
+2
(∂H(β, θ)
∂β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂H(β, θ)
∂θ
)
.
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3.3
We have shown that A and B are two uncorrelated and asymptotically Normal random
variables. Thus,
√
n
[
N̂RI>0e −NRI>0e
]→d N(0,ΣNRI>0e ).
The asymptotic zero mean of
√
n
[
N̂RI>0e −NRI>0e
]
is because of equicontinuity of process
√
nD(Pˆ − P ) and assumptions 1 and 2. Moreover,
ΣNRI>0e = var
(√
nN̂RI>0e
)
= 4
{
var(A) + var(B)
}
=
1− (NRI>0e )2
ρ
+ 4
(∂H(β, θ)
∂β
)T
Σ0(β)
(∂H(β, θ)
∂β
)
+ 4
(∂H(β, θ)
∂θ
)T
Σ1(θ)
(∂H(β, θ)
∂θ
)
+8
(∂H(β, θ)
∂β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂H(β, θ)
∂θ
)
,
where
H(β, θ) =
∫
Φ(
[
R1(θ,X, Y )−R0(β,X)
]
Σ
1/2
R (β, θ)
)dF1D(X, Y )
ΣR =
(∂R0(r,X)
∂r
|r=β
)T
Σ0(β)
(∂R0(r,X)
∂r
|r=β
)
+
(∂R1(s,X, Y )
∂s
|s=θ
)T
Σ1(θ)
(∂R1(s,X, Y )
∂s
|t=θ
)
−2(∂R0(r,X)
∂r
|r=β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂R1(s,X, Y )
∂s
|s=θ
)
.
When βˆ and θˆ have influence function ψ0i and ψ1i,
√
n(βˆ−β) = 1√
n
∑n
i=1 ψ0i(X)+op(1),
√
n(θˆ−
θ) = 1√
n
∑n
i=1 ψ1i(X, Y ) + op(1), we have that,
Σ0(β) = var(ψ0i(X)), Σ1(θ) = var(ψ1i(X, Y ))
cov
(√
n(βˆ − β),√n(θˆ − θ)) = cov(ψ0i(X), ψ1i(X, Y )).
10
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3.4
Similarly, we can derive the asymptotic result for N̂RI>0ne .
√
n
[
N̂RI>0ne −NRI>0ne
]→d N(0,ΣNRI>0ne ),
ΣNRI>0ne = var
(√
nN̂RI>0ne
)
=
1− (NRI>0ne )2
1− ρ + 4
(∂G(β, θ)
∂β
)T
Σ0(β)
(∂G(β, θ)
∂β
)
+ 4
(∂G(β, θ)
∂θ
)T
Σ1(θ)
(∂G(β, θ)
∂θ
)
+8
(∂G(β, θ)
∂β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂G(β, θ)
∂θ
)
,
where
G(β, θ) =
∫
Φ(
[
R0(β,X)−R1(θ,X, Y )
]
Σ
1/2
R (β, θ)
)dF0D¯(X, Y )
ΣR =
(∂R0(r,X)
∂r
|r=β
)T
Σ0(β)
(∂R0(r,X)
∂r
|r=β
)
+
(∂R1(s,X, Y )
∂s
|s=θ
)T
Σ1(θ)
(∂R1(s,X, Y )
∂s
|s=θ
)
−2(∂R0(r,X)
∂r
|r=β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂R1(s,X, Y )
∂s
|s=θ
)
.
4 Asymptotic Distribution of a Two-Category NRI
In this section, we consider the two-category NRI calculated based on a reclassification table
with risk threshold at t. NRI describes the “upward” and “downward” movements among
risk categories comparing the new model to the old model. Let r̂iskt(X, Y ) and r̂iskt(X)
denote the categorized risks with threshold t from the new model and from the old model,
11
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then the two-category NRI t is estimated as follows,
N̂RI te = Pˆ
(
r̂iskt(X, Y ) > r̂iskt(X)|D = 1
)− Pˆ(r̂iskt(X, Y ) < r̂iskt(X)|D = 1),
N̂RI tne = Pˆ
(
r̂iskt(X, Y ) < r̂iskt(X)|D = 0
)− Pˆ(r̂iskt(X, Y ) > r̂iskt(X)|D = 0),
N̂RI t = N̂RI te + N̂RI
t
ne.
With a single risk threshold at t, it can be shown that,
NRI te = TPR(t, R1(θ,X, Y ))− TPR(t, R0(β,X)),
NRI tne = FPR(t, R0(β,X))− FPR(t, R1(θ,X, Y )),
where TPR, FPR are the true positive rate and false positive rate.
12
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4.1
We consider N̂RI te first.
−√n(N̂RI te −NRI te)
= −√n{T̂PR(r, R1)− T̂PR(r, R0)− [TPR(t, R1)− TPR(t, R0)]}
= −√n{TPR(t, R1(θˆ,X, Y ))− TPR(t, R0(βˆ,X))− [TPR(t, R1(θ,X, Y ))− TPR(t, R0(β,X))]}
= −√n{[1− Fˆ1D(R−11 (θˆ, t))]− [1− Fˆ0D(R−10 (βˆ, t))]}
+
√
n
{[
1− F1D(R−11 (θ, t))
]− [1− F0D(R−10 (β, t))]}
=
√
n
{[
Fˆ1D(R
−1
1 (θˆ, t))− Fˆ0D(R−10 (βˆ, t))
]− [F1D(R−11 (θ, t))− F0D(R−10 (β, t))]}
=
√
n
{[
Fˆ1D(R
−1
1 (θ, t))− Fˆ0D(R−10 (β, t))
]− [F1D(R−11 (θ, t))− F0D(R−10 (β, t))]}
+
√
n
{[
F1D(R
−1
1 (θˆ, t))− F0D(R−10 (βˆ, t))
]− [F1D(R−11 (θ, t))− F0D(R−10 (β, t))]}+ op(1)
(since
√
n
{[
Fˆ1D(R
−1
1 (θˆ, t))− Fˆ0D(R−10 (βˆ, t))
]− [Fˆ1D(R−11 (θ, t))− Fˆ0D(R−10 (β, t))]}
−√n{[F1D(R−11 (θˆ, t))− F0D(R−10 (βˆ, t))]− [F1D(R−11 (θ, t))− F0D(R−10 (β, t))]}→p 0,
due to the equicontinuity of the process and assumption 3.)
= C +D
We know that
√
n
[
Fˆ1D(t1)−Fˆ0D(t2)−
(
F1D(t1)−F0D(t2)
)]
is a Gaussian process,
√
n
[
Fˆ1D(t1)−
Fˆ0D(t2) −
(
F1D(t1) − F0D(t2)
)] →d N(0, (F1D(t1) − F0D(t2))[1 − (F1D(t1) − F0D(t2))]/ρ),
where ρ = nD/n. Thus, the asymptotic variance of C is,
var(C)
.
= −1
ρ
[
F1D(R
−1
1 (θ, t))− F0D(R−10 (β, t))
]{
1 +
[
F1D(R
−1
1 (θ, t))− F0D(R−10 (β, t))
]}
=
1
ρ
[
TPR(t, R1(θ,X, Y ))− TPR(t, R0(β,X))
]{
1− [TPR(t, R1(θ,X, Y ))− TPR(t, R0(β,X))]}
=
1
ρ
NRI te
[
1−NRI te
]
13
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4.2
On the other hand, by Taylor expansion, we have,
D =
√
n
{[
F1D(R
−1
1 (θˆ, t))− F0D(R−10 (βˆ, t))
]− [F1D(R−11 (θ, t))− F0D(R−10 (β, t))]}
= f1D(R
−1
1 (θ, t))
(∂R−11 (θ, t)
∂θ
)T√
n(θˆ − θ)− f0D(R−10 (β, t))
(∂R−10 (β, t)
∂β
)T√
n(βˆ − β) + op(1)
=
(∂TPR(t, R0(β,X))
∂β
)T√
n(βˆ − β)− (∂TPR(t, R1(θ,X, Y ))
∂θ
)T√
n(θˆ − θ) + op(1).
Thus,
var(D) =
(∂TPR(t, R0(β,X))
∂β
)T
Σ0(β)
(∂TPR(t, R0(β,X))
∂β
)
+
(∂TPR(t, R1(θ,X, Y ))
∂θ
)T
Σ1(θ)
(∂TPR(t, R1(θ,X, Y ))
∂θ
)
−2(∂TPR(t, R0(β,X))
∂β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂TPR(t, R1(θ,X, Y ))
∂θ
)
.
In the above, assumption 4 guarantees random variable D is not degenerate. In contrast
to the derivation in section 3.2 of NRI>0e , this assumption is necessary for establishing
asymptotic Normality of the two-category NRI. This is because when assumption 4 fails,
var(C)
.
= 1
ρ
NRI te
[
1−NRI te
]
= 0.
4.3
Next, we compute cov(C,D). This includes covariances between
√
n(βˆ − β), √n(θˆ− θ) and
√
n(Fˆ0D − F0D),
√
n(Fˆ1D − F1D). Denote the influence functions of βˆ and θˆ by ψ0i and ψ1i,
respectively. We have
√
n(βˆ−β) = 1√
n
∑n
i=1 ψ0i(X)+op(1),
√
n(θˆ−θ) = 1√
n
∑n
i=1 ψ1i(X, Y )+
14
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op(1). Thus,
cov
(√
n(βˆ − β),√n(Fˆ0D(t)− F0D(t))
)
= cov
( 1√
n
n∑
i=1
ψ0i(X),
1√
n
n∑
i=1
I(XD ≤ t)− F0D(t)
)
= cov
(
ψ0i(XD), I(XD ≤ t)− F0D(t)
)
(since cases and controls are independent.)
= E
(
ψ0i(XD)
[
I(XD ≤ t)− F0D(t)
])
= E
(
ψ0i(XD)I(XD ≤ t)
)− F0D(t)E(ψ0i(XD)) ≡ Cβ,0(XD, t).
Similarly, we can derive that,
cov
(√
n(βˆ − β),√n(Fˆ1D(t)− F1D(t))
)
= E
(
ψ0i(XD)I(ZD ≤ t)
)− F1D(t)E(ψ0i(XD)) ≡ Cβ,1(ZD, t) = Cβ,1(XD, YD, t),
cov
(√
n(θˆ − θ),√n(Fˆ0D(t)− F0D(t))
)
= E
(
ψ1i(ZD)I(XD ≤ t)
)− F0D(t)E(ψ1i(ZD)) ≡ Cθ,0(ZD, t) = Cθ,0(XD, YD, t),
cov
(√
n(θˆ − θ),√n(Fˆ1D(t)− F1D(t))
)
= E
(
ψ1i(ZD)I(ZD ≤ t)
)− F1D(t)E(ψ1i(ZD)) ≡ Cθ,1(ZD, t) = Cθ,1(XD, YD, t).
15
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Thus,
cov(C,D)
=
(∂TPR(t, R0(β,X))
∂β
)T
cov
(√
n(βˆ − β),√n[Fˆ1D(R−11 (θ, t))− F1D(R−11 (θ, t))])
−(∂TPR(t, R0(β,X))
∂β
)T
cov
(√
n(βˆ − β),√n[Fˆ0D(R−10 (β, t))− F0D(R−10 (β, t))])
−(∂TPR(t, R1(θ,X, Y ))
∂θ
)T
cov
(√
n(θˆ − θ),√n[Fˆ1D(R−11 (θ, t))− F1D(R−11 (θ, t))])
+
(∂TPR(t, R1(θ,X, Y ))
∂θ
)T
cov
(√
n(θˆ − θ),√n[Fˆ0D(R−10 (β, t))− F0D(R−10 (β, t))])
=
(∂TPR(t, R0)
∂β
)T
Cβ,1(XD, YD, R
−1
1 (θ, t))−
(∂TPR(t, R0)
∂β
)T
Cβ,0(XD, R
−1
0 (β, t))
−(∂TPR(t, R1)
∂θ
)T
Cθ,1(XD, YD, R
−1
1 (θ, t)) +
(∂TPR(t, R1)
∂θ
)T
Cθ,0(XD, YD, R
−1
0 (β, t)).
Since C and D are asymptotically Normal random variables, we have
√
n
(
N̂RI te−NRI te
)
, or
equivalently
√
n
{
T̂PR(r, R1)− T̂PR(r, R0)−
[
TPR(t, R1)−TPR(t, R0)
]}
is asymptotically
Normal with mean 0 and variance ΣNRIte = var(C) + var(D) + 2cov(C,D).
4.4
Similarly, we can derive asymptotic result for NRI tne, or equivalently, FPR(t, R1(θ,X, Y ))−
FPR(t, R0(β,X)):
√
n
(
N̂RI tne −NRI tne
)→d N(0,ΣNRItne),
16
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where
ΣNRItne = var(E) + var(F ) + 2cov(E,F ),
E =
√
n
{[
Fˆ1D¯(R
−1
1 (θ, t))− Fˆ0D¯(R−10 (β, t))
]− [F1D¯(R−11 (θ, t))− F0D¯(R−10 (β, t))]},
F =
√
n
{[
F1D¯(R
−1
1 (θˆ, t))− F0D¯(R−10 (βˆ, t))
]− [F1D¯(R−11 (θ, t))− F0D¯(R−10 (β, t))]}.
var(E) =
1
1− ρNRI
t
ne
[
1−NRI tne
]
,
var(F ) =
(∂FPR(t, R0(β,X))
∂β
)T
Σ0(β)
(∂FPR(t, R0(β,X))
∂β
)
+
(∂FPR(t, R1(θ,X, Y ))
∂θ
)T
Σ1(θ)
(∂FPR(t, R1(θ,X, Y ))
∂θ
)
−2(∂FPR(t, R0(β,X))
∂β
)T
cov
(√
n(βˆ − β),√n(θˆ − θ))(∂FPR(t, R1(θ,X, Y ))
∂θ
)
,
cov(E,F ) =
(∂FPR(t, R0)
∂β
)T
C¯β,1(XD, YD, R
−1
1 (θ, t))−
(∂FPR(t, R0)
∂β
)T
C¯β,0(XD, R
−1
0 (β, t))
−(∂FPR(t, R1)
∂θ
)T
C¯θ,1(XD, YD, R
−1
1 (θ, t)) +
(∂FPR(t, R1)
∂θ
)T
C¯θ,0(XD, YD, R
−1
0 (β, t)).
C¯β,0(XD¯, t) = E
(
ψ0i(XD¯)I(XD¯ ≤ t)
)− F0D¯(t)E(ψ0i(XD¯)),
C¯β,1(XD¯, YD¯, t) = E
(
ψ0i(XD¯)I(ZD¯ ≤ t)
)− F1D¯(t)E(ψ0i(XD¯)),
C¯θ,0(XD¯, YD¯, t) = E
(
ψ1i(ZD¯)I(XD¯ ≤ t)
)− F0D¯(t)E(ψ1i(ZD¯)),
C¯θ,1(XD¯, YD¯, t) = E
(
ψ1i(ZD¯)I(ZD¯ ≤ t)
)− F1D¯(t)E(ψ1i(ZD¯)).
5 Sampling Distributions in Finite Samples
We have established asymptotic Normality for category-free and two-category NRIe and
NRIne. Another important question is how accurate the Normal approximation is in finite
samples. In this section, we perform simulations to examine sampling distributions of NRI
17
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statistics with quantile-quantile (QQ) plots.
We simulate data with risks following a logistic model since logistic regression is commonly
used in risk modeling. The same family of simulation models have been used by several
researchers to examine methodology related to incremental value [3, 4, 20]. Specifically,
Let ρ denote the disease prevalence and n denote the sample size. We first generate D ∼
Binomial(N, ρ). We then generate the baseline marker X ∼ N(0, 1) and the new marker
Y ∼ N(0, 1), independently in controls, and X ∼ N(µX , 1), Y ∼ N(µY , 1), independently
in cases. This guarantees the logistic model holds when X alone or X and Y are included
as predictors. This can be seen by Bayes rule,
P (D = 1|X = x) = P (X = x|D = 1)P (D = 1)
P (X = x|D = 1)P (D = 1) + P (X = x|D = 0)P (D = 0)
=
ρe−(x−µX)
2/2
ρe−(x−µX)2/2 + (1− ρ)e−x2/2 ,
logitP (D = 1|X = x) = log ρ
1− ρe
x2/2−(x−µX)2/2
= µXx− µ
2
X
2
+ log
ρ
1− ρ.
Similarly we have,
logitP (D = 1|X = x, Y = y) = µXx+ µY y − µ
2
X + µ
2
Y
2
+ log
ρ
1− ρ.
Thus the logistic model holds. Moreover, the coefficients in the models are βX = θX = µX
and θY = µY .
For our simulations, we always set ρ = 0.2 and µX = 0.74, while µY = 0, 0.37 or 0.74 to
reflect a new marker with no, modest or relatively large predictive strength. We consider
both the category-free NRI and the two-category NRI. For the two-category NRI, we used
the 20% quantile of R0(β,X) as risk threshold, which means the proportion of subjects
classified as “high risk” by the baseline risk model is about the same as the prevalence. This
18
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Figure 1: QQ plots of NRI>0e and NRI
>0
ne for a new marker with a modest incremental value
under various sample size.
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threshold was obtained empirically by simulating a data set of size 10,000,000.
Figure 1 is QQ plots of NRI>0e and NRI
>0
ne for a new marker with a modest incremental
value under various sample size. Figure 2 is QQ plots of NRI>0e and NRI
>0
ne when the
new marker has a relatively large incremental value. In both figures, the upper panel is for
NRI>0e and the bottom panel is for NRI
>0
ne . Sample size increases from left to right. In
both situations (modest or large incremental value), sampling distributions of NRI>0e and
NRI>0ne are quite close to Normal with a relatively small sample size, and the approximation
improves as sample size increases.
Figure 3 and Figure 4 are QQ plots of the two-category NRI with threshold at 20% risk
quantile for a new marker with a modest incremental value or with a relatively large incre-
mental value. Because of the discreteness of the two-category NRI introduced by the risk
threshold, a larger sample size is expected for asymptotic theory to take effect compared to
19
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Figure 2: QQ plots ofNRI>0e andNRI
>0
ne for a new marker with a relatively large incremental
value under various sample size.
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the category-free NRI. In addition, note that the sample sizes of Figure 3 are 1,000, 3,000
and 5,000, larger than the sample sizes of Figure 4, which are 1,000, 2,000 and 3,000. We
chose these sample sizes so that the plots can better characterize the distributional behavior
of NRI0.2e and NRI
0.2
ne as they move towards their limiting distributions. In both figures, we
can see the discreteness in the QQ plots. For the same sample size, sampling distribution
of the two-category NRI is closer to Normal when the new marker has a relatively large in-
cremental value than when it has only a modest incremental value. For example, at sample
size 3,000, the distributions of NRI0.2e and NRI
0.2
ne are relatively close to Normal in Figure
4 when the new marker has a relatively large incremental value, while in Figure 3, when the
incremental value is modest, the distributions of NRI0.2e and NRI
0.2
ne still have visible devi-
ation from Normal. As one expects, the Normal approximation becomes better as sample
size increases. However, compared with the category-free NRI, a much larger sample size is
required for sampling distributions of NRI0.2e and NRI
0.2
ne be to approximately Normal.
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Figure 3: QQ plots of NRI0.2e and NRI
0.2
ne for a new marker with a modest incremental value
under various sample size.
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Figure 4: QQ plots ofNRI0.2e andNRI
0.2
ne for a new marker with a relatively large incremental
value under various sample size.
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Figure 5: QQ plots of NRI>0e and NRI
>0
ne for a new marker with no incremental value under
various sample size.
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An unexpected finding suggested by Figure 3 is that, although the number of cases is much
smaller than the number of controls in our simulation settings, sampling distribution of
NRI0.2ne does not approach Normality faster than that of NRI
0.2
e . Their distributional be-
havior appears to depend more on the total sample size than on the numbers of cases or
controls.
As noted in section 3.2, assumption 4 is not essential for the sampling distribution of
category-free NRI to be asymptotic Normal. Here, we also examine the finite sample distri-
butional behavior of NRI>0e and NRI
>0
ne when the new marker has no incremental value at
all. The QQ plots are shown in Figure 5. The results suggest that, when the new marker
has an incremental value on the boundary zero, the category-free NRI statistics still have
asymptotically Normality, but a much larger sample size is needed to reach a good Normal
approximation compared with situations where the incremental value is away from zero.
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6 Discussion
In this paper, we examined the asymptotic and finite sample distributional behavior of
NRI statistics when risks are estimated from risk models fit to a dataset. We established
asymptotic Normality of NRI statistics, which provides some justification for construct-
ing confidence intervals via Normal approximation. For the category-free NRI, asymptotic
Normality can be reached with a rather small sample size when the new marker has an incre-
mental value away from zero. However, a large sample size is required for the two-category
event or nonevent NRI to get close to Normal, especially when the new marker has only a
modest incremental value. Moreover, a nonzero value of the incremental value of the new
marker (assumption 4) is a necessary assumption for establishing asymptotic Normality for
the two-category NRI. When this condition fails, simulation results suggest that the limit-
ing distribution of NRI te and NRI
t
ne is not Normal (results not shown). This is similar to
some other measures of incremental value, such as the integrated discrimination improve-
ment index [21]. For the category-free NRI, although this assumption is not necessary for
establishing its asymptotic Normality, a much larger sample size is needed for the distribu-
tion to be approximately Normal compared with situations when the incremental value is
away from zero.
However, the behavior of NRI statistics on the boundary zero, i.e., when the new marker has
no incremental value, is not the focus of our paper. This is because quantifying predictive
improvement is more of interests when the new marker is useful. Otherwise, for a marker
with unknown predictive ability, it is advised to first perform a test to determine whether
this marker has nonzero incremental value [3]. Nevertheless, we do not need to construct
such a test based on NRI>0 statistics, because the null hypothesis of zero value of NRI>0 is
equivalent to the null hypothesis that the coefficient of the marker in the risk model is zero,
for which more powerful tests can be constructed [3].
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In the derivation, we assumed the risk models used reflect the truth and did not consider
model misspecification. However, as argued by Pepe et al [3], poorly calibrated models are
not acceptable for risk prediction. The performance characteristics of a risk model should
be examined first. Only adequately calibrated models should advance to further evaluation
and potential adoption.
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